The divestiture is a clear positive catalyst—deleveraging, margin expansion, and sharper focus on higher-growth segments. Monitor the Q3 10-Q for the discontinued operations classification and any update on closing timeline. The reaffirmed guidance provides a floor, but the stock's reaction will hinge on the speed of debt reduction and any subsequent strategic moves (e.g., further portfolio rationalization or share buybacks).
Price Chart
Executive Summary
Clarivate announced a definitive agreement to sell its Life Sciences & Healthcare (LSH) segment to Altaris LLC for $600 million ($500M cash at closing, $25M deferred cash, $75M seller note). The transaction sharpens the company's focus on its Academia & Government and Intellectual Property segments, improves the financial profile by expanding Adjusted EBITDA margin 200bps, raising recurring revenue mix 300bps, and lowering capital intensity. Proceeds will be used to reduce debt targeting the 2028/2029 notes. The company reaffirmed its full-year 2026 outlook, which includes LSH segment results for the full year (discontinued ops from Q3) and a non-cash goodwill impairment of $225-$250M. The deal is expected to close by year-end.
Key Facts
- Definitive agreement to sell LSH segment to Altaris LLC for $600M total consideration: $500M cash at closing, $25M deferred cash, $75M seller note.
- Proceeds to be used to reduce debt (2028/2029 notes); net leverage expected to decline from ~4.0x to ~2.5x by 2029.
- Reaffirmed FY2026 outlook: Revenues (incl. discontinued ops) $2.30B–$2.42B, Adjusted EBITDA $980M–$1.04B, Adjusted Diluted EPS $0.70–$0.80, Free Cash Flow $365M–$435M.
- Expects $225M–$250M non-cash goodwill impairment on LSH segment, not impacting 2026 financial metrics.
- Divestiture improves recurring organic revenue mix from ~89% to ~92%, expands Adjusted EBITDA margin from ~42.75% to ~44.75%, and reduces capital expenditures by ~$60M.
- Transaction valued at 10x 2026T Adj. EBITDA less capital expenditures for LSH segment (~$120M EBITDA - ~$60M CapEx).
- Closing expected by year-end, subject to regulatory approvals and customary conditions.
Financial Impact
Sale provides $600M in gross proceeds; $525M cash. Non-cash goodwill impairment of $225–$250M. Annual interest savings ~$25M from debt reduction. LSH segment contributed ~$370M revenue and ~$120M Adj. EBITDA (midpoint of guidance).
Risk Factors
- Execution risk on closing, including regulatory approvals and potential delays.
- LSH segment revenue/EBITDA will be removed from continuing ops, reducing absolute revenue and EBITDA in 2027.
- High leverage remains (~4.0x net debt/EBITDA pre-transaction) despite debt reduction plan.
- Non-cash goodwill impairment of $225–$250M will reduce GAAP net income but not cash flows.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001764046-26-000085 |
| Exhibit: ex992lshdivestitureinves.htm | 0001764046-26-000085 |
| Document: clvt-20260706.htm | 0001764046-26-000085 |
| Document: 0001764046-26-000085-index-headers.html | 0001764046-26-000085 |
| Document: 0001764046-26-000085-index.html | 0001764046-26-000085 |
| Document: 0001764046-26-000085.txt | 0001764046-26-000085 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 8-K/A | $1.61 | awaiting T+20 | — | $1.87 (+16.15%) |
Oct 6, 2026 20d ago | 8-K | $1.47 | awaiting T+20 | — | $1.87 (+27.21%) |
Sep 24, 2026 4w ago | 8-K | $1.84 $1.85 | ▲ +0.54% | ▲ +0.96% | $1.87 (+1.63%) |
Sep 22, 2026 5w ago | Press Release | $1.89 $1.78 | ▼ −5.82% | ▼ −5.26% | $1.87 (−1.06%) |
Sep 17, 2026 5w ago | Press Release | $1.90 $1.74 | ▼ −8.42% | ▼ −9.88% | $1.87 (−1.58%) |
Aug 10, 2026 11w ago | Insider Cluster | $1.91 $1.91 | · 0.00% | ▲ +1.06% | $1.87 (−2.09%) |
Aug 3, 2026 12w ago | 144 | $1.97 $2.04 | ▼ −3.55% | ▼ −4.79% | $1.87 (+5.08%) |
Jul 6, 2026 16w ago | 8-K | $2.51 $1.94 | ▼ −22.71% | ▼ −24.04% | $1.87 (−25.50%) |
Jul 6, 2026 16w ago | 8-K | $2.44 $1.98 | ▼ −18.85% | ▼ −18.29% | $1.87 (−23.36%) |
Jun 8, 2026 20w ago | 8-K | $2.38 $2.51 | ▲ +5.46% | ▲ +4.02% | $1.87 (−21.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers